[250 Pages Report] The systemic lupus erythematosus (SLE) drugs market is projected to record a CAGR of 5% during the forecast period, up from US$ 183.3 Billion in 2020, to reach a valuation of US$ 329.18 Billion by 2032.
The systemic lupus erythematosus (SLE) drugs market is anticipated to show promising growth prospects owing to the prevalence of autoimmune diseases, particularly systemic lupus erythematosus (SLE).
Attributes | Details |
---|---|
Systemic Lupus Erythematosus (SLE) Drugs Market Value (2020) | US$ 183.3 Billion |
Systemic Lupus Erythematosus (SLE) Drugs Market (2032) | US$ 329.18 Billion |
CAGR (2022 to 2032) | 5% |
Sales of systemic lupus erythematosus (SLE) drugs is expected to rise with the introduction of novel biological therapies in the development pipeline. In addition to this, demand for systemic lupus erythematosus (SLE) drugs is rising due to the rising frequency of autoimmune illnesses, notably systemic lupus erythematosus (SLE).
This factor is anticipated to significantly influence the systemic lupus erythematosus (SLE) drugs market, as over 50% of SLE patients have lupus nephritis.
Some new potential medications in Phase III studies are also projected to contribute to the growth of the systemic lupus erythematosus (SLE) drugs market share.
Some of the key systemic lupus erythematosus (SLE) drugs trends promoting the demand for systemic lupus erythematosus (SLE) drugs market include clinicians only administering biologics when two or more non-biologic immunosuppressants have failed to ameliorate a patient's disease activity.
Several nations have developed payment schemes based on these criteria, which greatly boosted the sales of systemic lupus erythematosus (SLE) drugs.
In developed nations, demand for systemic lupus erythematosus (SLE) drugs is higher due to stronger healthcare infrastructure and coverage availability. In underdeveloped regions, high costs and a lack of government-funded coverage limit access to biologics.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global market for systemic lupus erythematosus (SLE) drugs is expected to expand due to the rising frequency of autoimmune illnesses, notably systemic lupus erythematosus (SLE). The development of newer SLE medicines increased availability of biosimilar pharmaceuticals, and increased support for developing research areas for new drug molecules are increasing the sales of systemic lupus erythematosus (SLE) drugs and propelling the global systemic lupus erythematosus (SLE) drugs market forward.
Increased awareness of illness diagnosis and treatment and constant research and development procedures for innovative therapeutic molecules are major drivers of the global systemic lupus erythematosus (SLE) drugs. Furthermore, the safety and quality of systemic lupus erythematous controlling therapy may provide a hurdle to the sales of systemic lupus erythematosus (SLE) drugs.
Global systemic lupus erythematosus (SLE) drugs market growth is fast in the North American region and is estimated to project remarkable CAGR growth throughout the forecast period.
In North America, the SLE is more prevalent among Hispanics, Asians, and Native Americans, according to the Centers for Disease Control and Prevention (CDC). It is anticipated that this factor will boost the demand for systemic lupus erythematosus (SLE) drugs in the region.
The second-largest and fastest-growing systemic lupus erythematosus (SLE) drugs market is Europe and is projected to reach nearly US$ 550 Mn and register a double-digit CAGR due to the higher prevalence of SLE in Europe. According to the Lupus Journal article, among the European countries, Sweden, Iceland, and Spain recorded the highest sales of systemic lupus erythematosus (SLE) drugs.
This is expected to be the primary driver for global systemic lupus erythematous drugs market growth in the US, France, Germany, Italy, Spain, the UK and Japan. Benlysta will lead sales of systemic lupus erythematosus (SLE) drugs in coming years because of its excellent safety profile as well as proven efficacy in clinical trials.
The key players in the global systemic lupus erythematous drugs market are Anthera Pharmaceuticals BMS, GSK, ImmuPharma, Merck Serono, UCB, Amgen, HGS, Immunomedics, Johnson and Johnson, MedImmune, Sanofi, Teva Pharmaceutical Industries.
Immunosuppressants by Roche (CellCept (Mycophenolate mofetil), by Novartis (Neoral (Cyclosporine)), by GSK (Imuran (Azathioprine)) are also commonly prescribed for SLE treatment
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Report Attribute | Details |
---|---|
Growth rate | CAGR of 5% from 2022 to 2032 |
Base year for estimation | 2021 |
Historical data | 2015 to 2020 |
Forecast period | 2022 to 2032 |
Quantitative units | Revenue in USD Million, volume in kilotons, and CAGR from 2022 to 2032 |
Report coverage | Revenue forecast, volume forecast, company ranking, competitive landscape, growth factors, and trends, Pricing Analysis, |
Segments covered | Drug Classes, Route of Administration, region |
Regional scope | North America; Western Europe; Eastern Europe; Middle East; Africa; ASEAN; South Asia; Rest of Asia; Australia and New Zealand |
Country scope | USA, Canada, Mexico, Germany, UK, France, Italy, Spain, Russia, Belgium, Poland, Czech Republic, China, India, Japan, Australia, Brazil, Argentina, Colombia, Saudi Arabia, UAE, Iran, South Africa |
Key companies profiled | Anthera Pharmaceuticals BMS; GSK; ImmuPharma; Merck Serono; UCB; Amgen; HGS; Immunomedics; Johnson and Johnson; MedImmune; Sanofi; Teva Pharmaceutical Industries. |
Customization scope | Free report customization (equivalent to up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options | Avail customized purchase options to meet your exact research needs. |
The systemic lupus erythematous (SLE) drugs market is likely to register a CAGR of 5% during the forecast period (2022-2032).
Key players holding substantial systemic lupus erythematous (SLE) drugs market share include Anthera Pharmaceuticals BMS, GSK, ImmuPharma, Merck Serono, UCB, Amgen, HGS, Immunomedics, Johnson and Johnson, MedImmune, Sanofi, Teva Pharmaceutical Industries.
As per the analysis, the systemic lupus erythematous (SLE) drugs market is likely to be US$ 329 Bn by 2032.
Demand for systemic lupus erythematous (SLE) drugs is likely to rise owing to the prevalence of autoimmune diseases, particularly systemic lupus erythematosus (SLE).
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2017-2021 and Forecast, 2022-2032
4.1. Historical Market Size Value (US$ Mn) Analysis, 2017-2021
4.2. Current and Future Market Size Value (US$ Mn) Projections, 2022-2032
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Molecule Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Mn) Analysis By Molecule Type, 2017-2021
5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Molecule Type, 2022-2032
5.3.1. Corticosteroids
5.3.2. Non-Steroidal Anti-inflammatory Drugs
5.3.3. Disease-Modifying Anti-Rheumatic Drugs
5.3.4. Antimalarial Drugs
5.3.5. BLyS-specific Inhibitors or Monoclonal Antibodies
5.3.6. Immunosuppressive Agents/Immune Modulators
5.3.7. Anticoagulants
5.4. Y-o-Y Growth Trend Analysis By Molecule Type, 2017-2021
5.5. Absolute $ Opportunity Analysis By Molecule Type, 2022-2032
Deep-dive segmentation will be available in the sample on request
6. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Distribution Channel
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Mn) Analysis By Distribution Channel, 2017-2021
6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Distribution Channel, 2022-2032
6.3.1. Hospital Pharmacies
6.3.2. Drug Stores
6.3.3. Pharmacies
6.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2017-2021
6.5. Absolute $ Opportunity Analysis By Distribution Channel, 2022-2032
Deep-dive segmentation will be available in the sample on request
7. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2017-2021
7.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2022-2032
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. East Asia
7.3.5. South Asia & Pacific
7.3.6. MEA
7.4. Market Attractiveness Analysis By Region
8. North America Market Analysis 2017-2021 and Forecast 2022-2032, By Country
8.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
8.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
8.2.1. By Country
8.2.1.1. U.K.
8.2.1.2. Canada
8.2.2. By Molecule Type
8.2.3. By Distribution Channel
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Molecule Type
8.3.3. By Distribution Channel
8.4. Key Takeaways
9. Latin America Market Analysis 2017-2021 and Forecast 2022-2032, By Country
9.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
9.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Molecule Type
9.2.3. By Distribution Channel
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Molecule Type
9.3.3. By Distribution Channel
9.4. Key Takeaways
10. Europe Market Analysis 2017-2021 and Forecast 2022-2032, By Country
10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. U.K.
10.2.1.3. France
10.2.1.4. Spain
10.2.1.5. Italy
10.2.1.6. Rest of Europe
10.2.2. By Molecule Type
10.2.3. By Distribution Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Molecule Type
10.3.3. By Distribution Channel
10.4. Key Takeaways
11. East Asia Market Analysis 2017-2021 and Forecast 2022-2032, By Country
11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
11.2.1. By Country
11.2.1.1. China
11.2.1.2. Japan
11.2.1.3. South Korea
11.2.2. By Molecule Type
11.2.3. By Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Molecule Type
11.3.3. By Distribution Channel
11.4. Key Takeaways
12. South Asia & Pacific Market Analysis 2017-2021 and Forecast 2022-2032, By Country
12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
12.2.1. By Country
12.2.1.1. India
12.2.1.2. Thailand
12.2.1.3. Indonesia
12.2.1.4. Malaysia
12.2.1.5. Singapore
12.2.1.6. Australia
12.2.1.7. New Zealand
12.2.1.8. Rest of South Asia & Pacific
12.2.2. By Molecule Type
12.2.3. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Molecule Type
12.3.3. By Distribution Channel
12.4. Key Takeaways
13. MEA Market Analysis 2017-2021 and Forecast 2022-2032, By Country
13.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
13.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
13.2.1. By Country
13.2.1.1. GCC Countries
13.2.1.2. South Africa
13.2.1.3. Israel
13.2.1.4. Rest of MEA
13.2.2. By Molecule Type
13.2.3. By Distribution Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Molecule Type
13.3.3. By Distribution Channel
13.4. Key Takeaways
14. Key Countries Market Analysis
14.1. U.K.
14.1.1. Pricing Analysis
14.1.2. Market Share Analysis, 2021
14.1.2.1. By Molecule Type
14.1.2.2. By Distribution Channel
14.2. Canada
14.2.1. Pricing Analysis
14.2.2. Market Share Analysis, 2021
14.2.2.1. By Molecule Type
14.2.2.2. By Distribution Channel
14.3. Brazil
14.3.1. Pricing Analysis
14.3.2. Market Share Analysis, 2021
14.3.2.1. By Molecule Type
14.3.2.2. By Distribution Channel
14.4. Mexico
14.4.1. Pricing Analysis
14.4.2. Market Share Analysis, 2021
14.4.2.1. By Molecule Type
14.4.2.2. By Distribution Channel
14.5. Germany
14.5.1. Pricing Analysis
14.5.2. Market Share Analysis, 2021
14.5.2.1. By Molecule Type
14.5.2.2. By Distribution Channel
14.6. U.K.
14.6.1. Pricing Analysis
14.6.2. Market Share Analysis, 2021
14.6.2.1. By Molecule Type
14.6.2.2. By Distribution Channel
14.7. France
14.7.1. Pricing Analysis
14.7.2. Market Share Analysis, 2021
14.7.2.1. By Molecule Type
14.7.2.2. By Distribution Channel
14.8. Spain
14.8.1. Pricing Analysis
14.8.2. Market Share Analysis, 2021
14.8.2.1. By Molecule Type
14.8.2.2. By Distribution Channel
14.9. Italy
14.9.1. Pricing Analysis
14.9.2. Market Share Analysis, 2021
14.9.2.1. By Molecule Type
14.9.2.2. By Distribution Channel
14.10. China
14.10.1. Pricing Analysis
14.10.2. Market Share Analysis, 2021
14.10.2.1. By Molecule Type
14.10.2.2. By Distribution Channel
14.11. Japan
14.11.1. Pricing Analysis
14.11.2. Market Share Analysis, 2021
14.11.2.1. By Molecule Type
14.11.2.2. By Distribution Channel
14.12. South Korea
14.12.1. Pricing Analysis
14.12.2. Market Share Analysis, 2021
14.12.2.1. By Molecule Type
14.12.2.2. By Distribution Channel
14.13. India
14.13.1. Pricing Analysis
14.13.2. Market Share Analysis, 2021
14.13.2.1. By Molecule Type
14.13.2.2. By Distribution Channel
14.14. Thailand
14.14.1. Pricing Analysis
14.14.2. Market Share Analysis, 2021
14.14.2.1. By Molecule Type
14.14.2.2. By Distribution Channel
14.15. Indonesia
14.15.1. Pricing Analysis
14.15.2. Market Share Analysis, 2021
14.15.2.1. By Molecule Type
14.15.2.2. By Distribution Channel
14.16. Malaysia
14.16.1. Pricing Analysis
14.16.2. Market Share Analysis, 2021
14.16.2.1. By Molecule Type
14.16.2.2. By Distribution Channel
14.17. Singapore
14.17.1. Pricing Analysis
14.17.2. Market Share Analysis, 2021
14.17.2.1. By Molecule Type
14.17.2.2. By Distribution Channel
14.18. Australia
14.18.1. Pricing Analysis
14.18.2. Market Share Analysis, 2021
14.18.2.1. By Molecule Type
14.18.2.2. By Distribution Channel
14.19. New Zealand
14.19.1. Pricing Analysis
14.19.2. Market Share Analysis, 2021
14.19.2.1. By Molecule Type
14.19.2.2. By Distribution Channel
14.20. GCC Countries
14.20.1. Pricing Analysis
14.20.2. Market Share Analysis, 2021
14.20.2.1. By Molecule Type
14.20.2.2. By Distribution Channel
14.21. South Africa
14.21.1. Pricing Analysis
14.21.2. Market Share Analysis, 2021
14.21.2.1. By Molecule Type
14.21.2.2. By Distribution Channel
14.22. Israel
14.22.1. Pricing Analysis
14.22.2. Market Share Analysis, 2021
14.22.2.1. By Molecule Type
14.22.2.2. By Distribution Channel
15. Market Structure Analysis
15.1. Competition Dashboard
15.2. Competition Benchmarking
15.3. Market Share Analysis of Top Players
15.3.1. By Regional
15.3.2. By Molecule Type
15.3.3. By Distribution Channel
16. Competition Analysis
16.1. Competition Deep Dive
16.1.1. Anthera Pharmaceuticals
16.1.1.1. Overview
16.1.1.2. Product Portfolio
16.1.1.3. Profitability by Market Segments
16.1.1.4. Sales Footprint
16.1.1.5. Strategy Overview
16.1.1.5.1. Marketing Strategy
16.1.2. GlaxoSmithKline Pharmaceuticals Limited
16.1.2.1. Overview
16.1.2.2. Product Portfolio
16.1.2.3. Profitability by Market Segments
16.1.2.4. Sales Footprint
16.1.2.5. Strategy Overview
16.1.2.5.1. Marketing Strategy
16.1.3. ImmuPharma PLC
16.1.3.1. Overview
16.1.3.2. Product Portfolio
16.1.3.3. Profitability by Market Segments
16.1.3.4. Sales Footprint
16.1.3.5. Strategy Overview
16.1.3.5.1. Marketing Strategy
16.1.4. Merck Serono
16.1.4.1. Overview
16.1.4.2. Product Portfolio
16.1.4.3. Profitability by Market Segments
16.1.4.4. Sales Footprint
16.1.4.5. Strategy Overview
16.1.4.5.1. Marketing Strategy
16.1.5. Johnson & Johnson Private Limited
16.1.5.1. Overview
16.1.5.2. Product Portfolio
16.1.5.3. Profitability by Market Segments
16.1.5.4. Sales Footprint
16.1.5.5. Strategy Overview
16.1.5.5.1. Marketing Strategy
16.1.6. Novartis AG
16.1.6.1. Overview
16.1.6.2. Product Portfolio
16.1.6.3. Profitability by Market Segments
16.1.6.4. Sales Footprint
16.1.6.5. Strategy Overview
16.1.6.5.1. Marketing Strategy
16.1.7. MedImmune
16.1.7.1. Overview
16.1.7.2. Product Portfolio
16.1.7.3. Profitability by Market Segments
16.1.7.4. Sales Footprint
16.1.7.5. Strategy Overview
16.1.7.5.1. Marketing Strategy
16.1.8. Sanofi
16.1.8.1. Overview
16.1.8.2. Product Portfolio
16.1.8.3. Profitability by Market Segments
16.1.8.4. Sales Footprint
16.1.8.5. Strategy Overview
16.1.8.5.1. Marketing Strategy
16.1.9. Teva Pharmaceutical Industries
16.1.9.1. Overview
16.1.9.2. Product Portfolio
16.1.9.3. Profitability by Market Segments
16.1.9.4. Sales Footprint
16.1.9.5. Strategy Overview
16.1.9.5.1. Marketing Strategy
16.1.10. HGS
16.1.10.1. Overview
16.1.10.2. Product Portfolio
16.1.10.3. Profitability by Market Segments
16.1.10.4. Sales Footprint
16.1.10.5. Strategy Overview
16.1.10.5.1. Marketing Strategy
17. Assumptions & Acronyms Used
18. Research Methodology
Explore Healthcare Insights
View Reports